Search Results
The Center for Biomedical Research, Tongji Hospital Research Building, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Search for other papers by Chunliang Yang in
Google Scholar
PubMed
Search for other papers by Junyi Li in
Google Scholar
PubMed
Search for other papers by Fei Sun in
Google Scholar
PubMed
Search for other papers by Haifeng Zhou in
Google Scholar
PubMed
Search for other papers by Jia Yang in
Google Scholar
PubMed
Search for other papers by Chao Yang in
Google Scholar
PubMed
Hyperglycemia is the consequence of blood glucose dysregulation and a driving force of diabetic complications including retinopathy, nephropathy and cardiovascular diseases. The serum and glucocorticoid inducible kinase-1 (SGK1) has been suggested in the modulation of various pathophysiological activities. However, the role of SGK1 in blood glucose homeostasis remains less appreciated. In this review, we intend to summarize the function of SGK1 in glucose level regulation and to examine the evidence supporting the therapeutic potential of SGK1 inhibitors in hyperglycemia. Ample evidence points to the controversial roles of SGK1 in pancreatic insulin secretion and peripheral insulin sensitivity, which reflects the complex interplay between SGK1 activation and blood glucose fluctuation. Furthermore, SGK1 is engaged in glucose absorption and excretion in intestine and kidney and participates in the progression of hyperglycemia-induced secondary organ damage. As a net effect, blockage of SGK1 activation via either pharmacological inhibition or genetic manipulation seems to be helpful in glucose control at varying diabetic stages.
Search for other papers by Zeming Liu in
Google Scholar
PubMed
Search for other papers by Di Hu in
Google Scholar
PubMed
Search for other papers by Yihui Huang in
Google Scholar
PubMed
Search for other papers by Sichao Chen in
Google Scholar
PubMed
Search for other papers by Wen Zeng in
Google Scholar
PubMed
Search for other papers by Ling Zhou in
Google Scholar
PubMed
Search for other papers by Wei Zhou in
Google Scholar
PubMed
Search for other papers by Min Wang in
Google Scholar
PubMed
Search for other papers by Haifeng Feng in
Google Scholar
PubMed
Search for other papers by Wei Wei in
Google Scholar
PubMed
Search for other papers by Chao Zhang in
Google Scholar
PubMed
Search for other papers by Danyang Chen in
Google Scholar
PubMed
Search for other papers by Liang Guo in
Google Scholar
PubMed
Objectives
Controversies regarding factors associated with distant metastasis in pediatric thyroid cancer remain among the scientific community. The aim of this study was to investigate factors influencing distant metastasis in pediatric thyroid cancer.
Methods
We reviewed 1376 patients (aged 2 to 18 years) with thyroid cancer treated between 2003 and 2014. Data collected and analyzed included sex, race, age at diagnosis, year of diagnosis, pathological type, number of tumor foci, tumor extension, T-stage, N-stage, surgical procedure and radiation. Univariate and multivariate analyses were conducted to evaluate factors influencing distant metastasis of pediatric thyroid cancer.
Results
In the univariate analysis, factors influencing distant metastasis of thyroid cancer were age at diagnosis (P < 0.001), N-stage (P < 0.001), number of tumor foci (P = 0.003), tumor extension (P < 0.001) and T-stage (T1 vs T2 (P = 0.803), T3 (P < 0.001) and T4 (P < 0.001)). In multivariate analysis, factors influencing distant metastasis of thyroid cancer were age at diagnosis (P = 0.001), N-stage (P < 0.001) and T-stage (T1 vs T3 (P = 0.036) and T4 (P < 0.001)). Sex, race, year of diagnosis, pathological type, number of tumor foci, tumor extension, surgical procedure and radiation had no significant influence on distant metastasis (all P > 0.05). Furthermore, according to chi-squared test, younger pediatric thyroid cancer patients with higher T- and N-stages are more likely to have distant metastasis.
Conclusion
Age at diagnosis, T-stage and N-stage influence distant metastasis of thyroid cancer patients aged 2 to 18 years; accordingly, more radical treatments may need to be used for patients with those risk elements.
